Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
Benzinga • 602 days
Low Materiality0/10
Information
Friday, the FDA approved Argenx SE's ARGX Vyvgart Hytrulo for use in patients with chronic inflammat...
Original sourceAI Summary
- FDA approved ARGX Vyvgart Hytrulo for use in CIDP patients. - Vyvgart Hytrulo is the first FcRn blocker approved for CIDP. - ADHERE Study showed 61% reduction in relapse risk with Vyvgart Hytrulo. - Estimated annual net price per patient is $450,000 for CIDP treatment. Price Impact Rating: Bullish Impact Horizon Rating: Long-term Type: Industry News
Market-Moving
- FDA approved ARGX Vyvgart Hytrulo for use in CIDP patients.
- Vyvgart Hytrulo is the first FcRn blocker approved for CIDP.
- ADHERE Study showed 61% reduction in relapse risk with Vyvgart Hytrulo.
Key Facts
- FDA approved ARGX Vyvgart Hytrulo for use in CIDP patients.
- Vyvgart Hytrulo is the first FcRn blocker approved for CIDP.
- ADHERE Study showed 61% reduction in relapse risk with Vyvgart Hytrulo.
- Estimated annual net price per patient is $450,000 for CIDP treatment.